Prestige Consumer Healthcare Takes Deep International Breath With Breathe Right Deal
PCH using available cash and a loan to acquire Breathe Right nasal strips and nine other OTC brands from Foundation Consumer Healthcare for $1.045bn. Breathe Right accounts for two-thirds of the portfolio’s revenue and will be Prestige’s largest seller.
HBW Insight - April 7, 2026

Praxis Adds To Neuroscience Momentum With Epilepsy Trial Success
Elsunersen significantly reduced seizures in children with an inherited epilepsy condition, bolstering Praxis’ hopes of building a multi-billion dollar neuroscience portfolio.
Scrip - April 7, 2026

Japan: Firms Can Trigger OTC Reclassification Process Under New Scheme
Japan has introduced a new framework that allows manufacturers to trigger product?specific OTC reclassification reviews when real?world safety data supports broader consumer access, while maintaining controls for higher?risk products.
HBW Insight - April 7, 2026

Stock Watch: War! What Is It Good For?
The trade wars of 2025 resulted in dollar weakness, which boosted revenues of global pharma companies reporting in other currencies. But the different war in the Middle East this year may reverse that advantage and benefit US pharma companies in their first-quarter results.
Scrip - April 7, 2026

Venture Life Growing Hormonal Health Offering In US and UK
Venture Life is finding success with new product offerings under its H&H brand in the hormonal health dietary supplements category in both the US and UK.
HBW Insight - April 7, 2026

Phase III Success Puts Aurobindo In Xolair Biosimilars Race
Aurobindo’s CuraTeQ has reported positive Phase III data for its omalizumab biosimilar BP11 and targets US and EU filings by mid-2026, as competition intensifies around Roche’s multibillion-dollar Xolair franchise.
Generics Bulletin - April 7, 2026

Hikma And Glenmark’s Ryaltris Break-Up Illustrates Shifts In Strategies
Hikma and Glenmark’s decision to break off their US marketing alliance on Ryaltris provides insights into where both firms see their priorities.
Generics Bulletin - April 7, 2026

Sanofi’s Lunsekimig Delivers In Respiratory Phase II Studies, Misses In Dermatitis
Sanofi reported mixed Phase II results for lunsekimig, with positive data from a pair of respiratory disease trials and a miss in atopic dermatitis, while analysts continue to anchor expectations on its late-stage development in asthma and related indications.
Scrip - April 7, 2026

Are AI Device Regulations Forgetting The Human Factor?
Technical regulations for AI medical devices may not survive contact with humans. A research team from the Dresden University of Technology investigates how regulators and manufactures can account for human error in AI device deployment.
Medtech Insight - April 7, 2026

VISUfarma Gives Lupin Platform For Global Ophthalmology Push
Lupin has completed its €190m acquisition of VISUfarma, adding a 60-plus product ophthalmology portfolio and EU5 footprint, as it looks to scale its specialty business and build a global platform beyond traditional generics.
Generics Bulletin - April 7, 2026

Tacrolimus Acquisition Highlights CNX Strategy In Niche Generics
CNX Therapeutics has acquired rights to a generic tacrolimus infusion from Pharmanovia, marking its entry into an originator-only transplant segment and advancing its European strategy in critical care and CNS, with launches planned across key EU markets.
Generics Bulletin - April 7, 2026

MHRA Wants To Keep US FDA Close, And EU Closer
As the UK MHRA’s CE marking consultation draws to a close, the agency is reinforcing its intent to work more deeply on reciprocal device regulatory processes with the US FDA.
Medtech Insight - April 7, 2026

Podcast: Inside Step Pharma’s Pan?Cancer Ambition
Andrew Parker, CEO at Step Pharma, outlined the company’s “pipeline in a product” strategy as it seeks to develop a targeted approach to blood cancers and solid tumors by inhibiting CTSP1 enzyme.
In Vivo - April 7, 2026

Brain-Computer Interfaces Outrun Insurance
Lee Fleisher, former chief medical officer at CMS, fears that the lack of an insurance coverage framework for implantable brain-computer interfaces could leave these technologies out of reach for patients.
In Vivo - April 7, 2026

EMA Explains How To Use ‘Emerging’ 3D Printing Technology For Solid Oral Drugs
EMA says 3D printing is an emerging technology with great potential in pharmaceutical applications.
HBW Insight - April 7, 2026

Ingredient Amounts OK On NAD+ Supplement Label, In Advertising Not So Much
Iron Rock Ventures’ Supplement Facts Label information for its thinbi NAD+ supplement doesn’t violate FDA regulations, but National Advertising Division attorneys submit their questions about its advertising ingredient claims to federal and state regulators.
HBW Insight - April 7, 2026

Europe’s Beauty Leaders Sound Alarm Over Regulatory Roadblocks To Innovation
The Value of Beauty Alliance, a collaboration of 17 personal care and beauty companies, met with European lawmakers March 17 urging them to remove regulatory red tape that is hampering R&D and making the EU less competitive.
HBW Insight - April 7, 2026